{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-395031","form_type":"8-K","ticker":"BLSM","cik":"0001839970","company_name":"BlossomHill Therapeutics, Inc.","filed_at":"2026-09-18T11:15:07+00:00","discovered_at":"2026-09-18T11:20:10.351325+00:00","generated_at":"2026-09-18T11:20:15.822391+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BlossomHill Q2 net loss $23.8M; IPO raises $168.3M; FDA Fast Track for lung cancer drug","bullets":["Q2 2026 net loss $23.8M ($8.75/share) vs $13.2M ($5.51/share) in Q2 2025.","R&D expenses $21.4M (up from $12.5M); G&A $3.3M (up from $1.6M).","Cash $95.4M at June 30; August IPO gross proceeds $168.3M fund ops into Q2 2028.","FDA Fast Track granted for BH-30643 in EGFR C797S-positive NSCLC after 3rd-gen TKI.","Phase 1 SOLARA data: 45% ORR, 88% DCR in C797S-resistant patients; more milestones ahead."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-395031","json":"https://secwatch.observer/filing/0001193125-26-395031.json","markdown":"https://secwatch.observer/filing/0001193125-26-395031.md","text":"https://secwatch.observer/filing/0001193125-26-395031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1839970/000119312526395031/0001193125-26-395031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1839970/000119312526395031/d266261d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-18T11:20:15.822391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}